Industry News
Plantigens: best prospect for defeating Malaria?
Australian malaria vaccine researcher Professor Ross Coppell says smallpox was eradicated from the planet because the mass vaccination campaign employed a powdered formulation of dried, attenuated virus. [ + ]
Queensland Biobus stops at Gympie
The Queensland BioBus is stopping in Gympie this week to encourage more young people to take up a career in science. [ + ]
Quicker, less invasive cancer detection
A Mississippi State research team is developing a cancer screening process that may allow physicians to more quickly diagnose malignancies without performing invasive biopsies. Utilising laser-induced breakdown spectroscopy, or LIBS, scientists are seeking to precisely distinguish malignant and normal cells in real time by inserting a single optical fibre microprobe directly into suspicious tissue for a cancer diagnosis, including breast cancer.
[ + ]Beckman Coulter/Princeton BioMeditech agreement
In a move that underscores its growing commitment to the market for rapid diagnostic medical test products, Beckman Coulter has entered into a supply relationship with Princeton BioMeditech (PBM). Under the agreement, PBM will supply a wide range of rapid diagnostic tools used at the point of medical care to Beckman Coulter's Primary Care Diagnostics business unit (PCD).
[ + ]The LIMS revolution - where is it headed: an Australian perspective
Laboratory information management systems, or LIMS as it is popularly known, has been gaining good acceptance world over. Australia is not far behind in adopting this new technology. LIMS has been there in the market for over 10 years now and many organisations are now implementing their second or third generation of LIMS.
[ + ]Chinese companies invest in Melbourne
Melbourne biotech is benefiting from a recent business mission to China led by the city's Lord Mayor John So. [ + ]
Imugene licenses poultry productivity product to Merial
Sydney animal-health biotech Imugene (ASX:IMU) has finalised an exclusive sub-license agreement granting international livestock health company and Merck-Aventis subsidiary Merial the global rights to develop and sell Imugene's poultry productivity enhancing product. [ + ]
Panbio develops new type of antibody assay
Brisbane medical diagnostics developed Panbio (ASX:PBO) believes it has achieved a milestone in its efforts to develop a new type of antibody assay capable of directly detecting target antigens at low concentrations in antigenically complex biological fluids. [ + ]
In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies. [ + ]
Mini analysis tools coming to market
Scientists at the University of York, who have developed miniaturised tools for chemical and biological analysis, have won a major injection of growth capital to produce them commercially.
[ + ]Norwood to commence phase II cancer vaccine trial
Melbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed an agreement for a phase II collaboration with the University of Texas MD Anderson Cancer Centre of Houston to determine whether its investigational melanoma cancer vaccine generates an enhanced immune response. [ + ]
Resonance Health patent granted
Perth based Resonance Health (ASX:RHT) has been granted its first European patent. [ + ]
Prozac prevents onset of Huntington's disease in mice
A collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice. [ + ]
Funding for medical research and Thank You Day campaign launch
The latest commonwealth government funding announcement for health and medical research will see AUD$292 million allocated to more than 600 projects across 52 Australian universities, hospitals and medical research institutes. [ + ]
Peplin obtains positive anti-leukemia results for drug candidate in mouse model
Peplin (ASX:PEP) has produced positive results from an initial efficacy study of its drug candidate PEP005 IV in a mouse model of acute myeloid leukemia. [ + ]